Ozenoxacin

Summary

Ozenoxacin (CHEMBL3990047) is an approved small molecule (ATC D06AX14); indicated across 2 conditions including impetigo and injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06AX14
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 363.4 Da · C21H21N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990047
Name	Ozenoxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9863827
ATC	D06AX14
Molecular formula	C21H21N3O3
Molecular weight	363.4
InChIKey	XPIJWUTXQAGSLK-UHFFFAOYSA-N

SMILES: CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C

IUPAC name: 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxoquinoline-3-carboxylic acid

Also known as: Ozenoxacin, Ozenoxacine, Ozenoxacino, T-3912, Xepi, OZENOXACIN

Patent coverage: 119 distinct patent families (270 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 213 (79%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
impetigo	4	MONDO:0004592	EFO:1000714
injury	2	MONDO:0021178	EFO:0000546

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01397461	PHASE3	COMPLETED	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT02090764	PHASE3	COMPLETED	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT01005771	PHASE2	COMPLETED	Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).